2017
DOI: 10.22328/2077-9828-2017-9-3-39-46
|View full text |Cite
|
Sign up to set email alerts
|

Pegylated Interferon and Ribavirin as an Available Variant of Antiviral Therapy for Chronic Hepatitis C in Hiv Infected

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The object of the study was the substance of modified PEGylated interferon alfa-2b (Binnopharm JSC, Russia), which has improved biopharmaceutical characteristics compared to interferon alfa-2b, in particular, greater stability, shelf life, better permeability, and bioavailability [2,19]. Solid fats Witepsol® H15, Witepsol® W 35, Suppocire® BS2X and Suppocire® BM (EP 01/2009: 0462) were used as the basis for suppositories (table 1).…”
Section: Methodsmentioning
confidence: 99%
“…The object of the study was the substance of modified PEGylated interferon alfa-2b (Binnopharm JSC, Russia), which has improved biopharmaceutical characteristics compared to interferon alfa-2b, in particular, greater stability, shelf life, better permeability, and bioavailability [2,19]. Solid fats Witepsol® H15, Witepsol® W 35, Suppocire® BS2X and Suppocire® BM (EP 01/2009: 0462) were used as the basis for suppositories (table 1).…”
Section: Methodsmentioning
confidence: 99%